BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT00410059
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib — DRUG
    150 mg by mouth daily x 28 days

Study Details

The goal of this clinical research study is to learn if erlotinib hydrochloride (OSI-774, Tarceva®) can help to control NSCLC. The safety of this drug will also be studied, as well as the drug's effect on different cells in the body and the participants' overall response.

Key Dates

First listed
Dec 12, 2006
Start date
Nov 30, 2006
Status verified
Jul 2017
Primary completion
Jul 31, 2016
Completion
Jul 31, 2016

Study Design

Enrollment
59 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Erlotinib
    Erlotinib 150 mg by mouth daily x 28 days.

Primary Outcome Measure

8 Week Progression-Free Survival Rate (i.e. Disease Control Rate) [ Time Frame: Radiographic evaluation after cycle 2 (8 weeks of therapy) ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
University of Texas MD Anderson Cancer Center· Houston, TX

Related Studies